
<p>{{DiseaseDisorder infobox}}
<b>Acute myeloid leukemia</b> (<b>AML</b>), also known as <b>acute myelogenous leukemia</b>, is a <a href="/wiki/Cancer" id="w">cancer</a> of the <a href="/wiki/Myeloid" id="w">myeloid</a> line of <a href="/wiki/White_blood_cell" id="w">white blood cells</a>, characterized by the rapid proliferation of abnormal cells which accumulate in the <a href="/wiki/Bone_marrow" id="w">bone marrow</a> and interfere with <a href="/wiki/Haematopoiesis" id="w">the production of normal blood cells</a>. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the <a href="/wiki/United_States" id="w">United States</a>,<sup id="_ref-cancerstats_a" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup> its incidence is expected to increase as the population ages.</p>
<p>The symptoms of <b>AML</b> are caused by replacement of normal bone marrow with leukemic cells, resulting in a drop in <a href="/wiki/Red_blood_cell" id="w">red blood cells</a>, <a href="/wiki/Platelet" id="w">platelets</a>, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of AML remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.</p>
<p>Acute myeloid leukemia is a potentially curable disease; but only a minority of patients are cured with current therapy. AML is treated initially with <a href="/wiki/Chemotherapy" id="w">chemotherapy</a> aimed at inducing a <a href="/wiki/Remission_(medicine)" id="w">remission</a>; some patients may go on to receive a <a href="/wiki/Stem_cell_transplant" id="w">hematopoietic stem cell transplant</a>.</p>
<p>Areas of active research in acute myeloid leukemia include further elucidation of the cause of AML, identification of better <a href="/wiki/Prognosis" id="w">prognostic indicators</a>, development of new methods of detecting residual disease after treatment, and the development of new drugs and <a href="/wiki/Targeted_therapy" id="w">targeted therapies</a>.</p>
<a id="History" name="History"></a><h1>History</h1>
<p>The first published description of a case of leukemia in medical literature dates to <a href="/wiki/1827" id="w">1827</a>, when a French physician named <a href="/wiki/Alfred-Armand-Louis-Marie_Velpeau" id="w">Alfred-Armand-Louis-Marie Velpeau</a> described a 63-year-old florist who developed an illness characterized by fever, weakness, <a href="/wiki/Nephrolithiasis" id="w">urinary stones</a>, and substantial <a href="/wiki/Hepatosplenomegaly" id="w">enlargement of the liver and spleen</a>. Velpeau noted that the blood of this patient had a consistency &#34;like gruel&#34;, and speculated that the appearance of the blood was due to white corpuscles.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[2]</a></sup> In <a href="/wiki/1845" id="w">1845</a>, a series of patients who died with enlarged spleens and changes in the &#34;colors and consistencies of their blood&#34; was reported by the <a href="/wiki/Edinburgh" id="w">Edinburgh</a>-based <a href="/wiki/Pathologist" id="w">pathologist</a> J.H. Bennett; he used the term &#34;leucocythemia&#34; to describe this pathological condition.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[3]</a></sup></p>
<p>The term &#34;leukemia&#34; was coined by <a href="/wiki/Rudolf_Virchow" id="w">Rudolf Virchow</a>, the renowned German <a href="/wiki/Pathologist" id="w">pathologist</a>, in <a href="/wiki/1856" id="w">1856</a>. As a pioneer in the use of the <a href="/wiki/Light_microscope" id="w">light microscope</a> in pathology, Virchow was the first to describe the abnormal excess of white blood cells in patients with the clinical syndrome described by Velpeau and Bennett. As Virchow was uncertain of the <a href="/wiki/Etiology" id="w">cause</a> of the white blood cell excess, he used the purely descriptive term &#34;leukemia&#34; (Greek: &#34;white blood&#34;) to refer to the condition.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[4]</a></sup></p>
<p>Further advances in the understanding of acute myeloid leukemia occurred rapidly with the development of new technology. In <a href="/wiki/1877" id="w">1877</a>, <a href="/wiki/Paul_Ehrlich" id="w">Paul Ehrlich</a> developed a technique of <a href="/wiki/Staining_(biology)" id="w">staining</a> blood films which allowed him to describe in detail normal and abnormal white blood cells. <a href="/wiki/Wilhelm_Ebstein" id="w">Wilhelm Ebstein</a> introduced the term <i>&#34;acute leukemia&#34;</i> in <a href="/wiki/1889" id="w">1889</a> to differentiate rapidly progressive and fatal leukemias from the more indolent <a href="/wiki/Chronic_leukemia" id="w">chronic leukemias</a>.<sup id="_ref-5" class="reference"><a href="#_note-5" title="">[5]</a></sup> The term &#34;myeloid&#34; was coined by Neumann in 1869, as he was the first to recognize that white blood cells were made in the bone marrow (<a href="/wiki/Ancient_Greek" id="w">Greek</a>: µυєλός, <i>myelos</i> = (bone) marrow) as opposed to the <a href="/wiki/Spleen" id="w">spleen</a>. The technique of <a href="/wiki/Bone_marrow_examination" id="w">bone marrow examination</a> to diagnose leukemia was first described in <a href="/wiki/1879" id="w">1879</a> by Mosler.<sup id="_ref-6" class="reference"><a href="#_note-6" title="">[6]</a></sup> Finally, in <a href="/wiki/1900" id="w">1900</a> the <a href="/wiki/Myeloblast" id="w">myeloblast</a>, which is the malignant cell in AML, was characterized by Naegeli, who divided the leukemias into <i>myeloid</i> and <i>lymphocytic</i>.<sup id="_ref-7" class="reference"><a href="#_note-7" title="">[7]</a></sup>
<sup id="_ref-8" class="reference"><a href="#_note-8" title="">[8]</a></sup></p>
<a id="Signs_and_symptoms" name="Signs_and_symptoms"></a><h1>Signs and symptoms</h1>
<p>Most signs and symptoms of AML are due to an increased number of malignant white blood cells displacing or otherwise interfering with <a href="/wiki/Haematopoiesis" id="w">production of normal blood cells</a> in the <a href="/wiki/Bone_marrow" id="w">bone marrow</a>. A lack of normal white blood cell production makes the patient susceptible to infections (while the leukemic cells themselves are derived from white blood cell precursors, they have no infection-fighting capacity).<sup id="_ref-symptoms_a" class="reference"><a href="#_note-symptoms" title="">[9]</a></sup> A lack of red blood cells (<a href="/wiki/Anemia" id="w">anemia</a>) can cause fatigue, paleness, and shortness of breath. A lack of <a href="/wiki/Platelet" id="w">platelets</a> can lead to easy bruising or bleeding with minor trauma.</p>
<p>The early signs of AML are often non-specific, and may be similar to those of <a href="/wiki/Influenza" id="w">influenza</a> or other common illnesses. Some generalized symptoms include <a href="/wiki/Fever" id="w">fever</a>, <a href="/wiki/Fatigue_(physical)" id="w">fatigue</a>, <a href="/wiki/Weight_loss" id="w">weight loss</a> or <a href="/wiki/Loss_of_appetite" id="w">loss of appetite</a>, <a href="/wiki/Dyspnea" id="w">shortness of breath</a> with exertion, <a href="/wiki/Anemia" id="w">anemia</a>, easy <a href="/wiki/Bruising" id="w">bruising</a> or <a href="/wiki/Bleeding" id="w">bleeding</a>, <a href="/wiki/Petechia" id="w">petechiae</a> (flat, pin-head sized spots under the skin caused by bleeding), <a href="/wiki/Bone_pain" id="w">bone pain</a> and <a href="/wiki/Joint_pain" id="w">joint pain</a> and persistent or frequent <a href="/wiki/Infections" id="w">infections</a>.<sup id="_ref-symptoms_b" class="reference"><a href="#_note-symptoms" title="">[9]</a></sup></p>
<p><a href="/wiki/Splenomegaly" id="w">Enlargement of the spleen</a> may occur in AML, but it is typically mild and <a href="/wiki/Asymptomatic" id="w">asymptomatic</a>. <a href="/wiki/Lymphadenopathy" id="w">Lymph node swelling</a> is rare in AML, in contrast to <a href="/wiki/Acute_lymphoblastic_leukemia" id="w">acute lymphoblastic leukemia</a>. The skin is involved about 10% of the time in the form of <a href="/wiki/Chloroma" id="w">leukemia cutis</a>. Rarely, <a href="/wiki/Sweet_syndrome" id="w">Sweet&#39;s syndrome</a>, a <a href="/wiki/Paraneoplastic_syndrome" id="w">paraneoplastic</a> inflammation of the skin, can occur with AML.<sup id="_ref-symptoms_c" class="reference"><a href="#_note-symptoms" title="">[9]</a></sup></p>
<p>Some patients with AML may experience swelling of the gums because of infiltration of leukemic cells into the gum tissue. Rarely, the first sign of leukemia may be the development of a solid leukemic mass or tumor outside of the <a href="/wiki/Bone_marrow" id="w">bone marrow</a>, called a <a href="/wiki/Chloroma" id="w">chloroma</a>. Occasionally, a person may show <a href="/wiki/Asymptomatic" id="w">no symptoms</a>, and the leukemia may be discovered incidentally during a routine blood test.<sup id="_ref-10" class="reference"><a href="#_note-10" title="">[10]</a></sup></p>
<a id="Causes" name="Causes"></a><h1>Causes</h1>
<p>A number of risk factors for developing AML have been identified, including:
</p>
<ul>
<li>&#34;Pre-leukemic&#34; blood disorders such as <a href="/wiki/Myelodysplastic_syndrome" id="w">myelodysplastic</a> or <a href="/wiki/Myeloproliferative_syndrome" id="w">myeloproliferative</a> syndromes can evolve into AML; the exact risk depends on the type of MDS/MPS.<sup id="_ref-11" class="reference"><a href="#_note-11" title="">[11]</a></sup></li>
<li>Exposure to <a href="/wiki/Chemotherapy" id="w">anti-cancer chemotherapy</a>, in particular <a href="/wiki/Alkylating_antineoplastic_agent" id="w">alkylating agents</a>, can increase the risk for the subsequent development of AML. The risk is highest about 3–5 years after chemotherapy.<sup id="_ref-12" class="reference"><a href="#_note-12" title="">[12]</a></sup> Other chemotherapy agents, specifically <a href="/wiki/Podophyllotoxin" id="w">epipodophyllotoxins</a> and <a href="/wiki/Anthracycline" id="w">anthracyclines</a>, have also been associated with treatment-related leukemia. These treatment-related leukemias are often associated with specific chromosomal abnormalities in the leukemic cells.<sup id="_ref-13" class="reference"><a href="#_note-13" title="">[13]</a></sup></li>
<li><a href="/wiki/Ionizing_radiation" id="w">Ionizing radiation</a> exposure can increase the risk of AML. Survivors of the <a href="/wiki/Atomic_bombings_of_Hiroshima_and_Nagasaki" id="w">atomic bombings of Hiroshima and Nagasaki</a> had an increased rate of AML,<sup id="_ref-14" class="reference"><a href="#_note-14" title="">[14]</a></sup> as did <a href="/wiki/Radiologist" id="w">radiologists</a> exposed to high levels of <a href="/wiki/X-ray" id="w">X-rays</a> prior to the adoption of modern radiation safety practices.<sup id="_ref-15" class="reference"><a href="#_note-15" title="">[15]</a></sup></li>
<li>Occupational chemical exposure to <a href="/wiki/Benzene" id="w">benzene</a> and other <a href="/wiki/Organic_solvent" id="w">aromatic organic solvents</a> is controversial as a cause of AML. Benzene and many of its derivatives are known to be <a href="/wiki/Carcinogenic" id="w">carcinogenic</a> <i>in vitro</i>. While some studies have suggested a link between occupational exposure to benzene and increased risk of AML,<sup id="_ref-16" class="reference"><a href="#_note-16" title="">[16]</a></sup> others have suggested that the attributable risk, if any, is slight.<sup id="_ref-17" class="reference"><a href="#_note-17" title="">[17]</a></sup></li>
<li>Several <a href="/wiki/Congenital" id="w">congenital</a> conditions may increase the risk of leukemia; the most common is probably <a href="/wiki/Down_syndrome" id="w">Down syndrome</a>, which is associated with a 10- to 18-fold increase in the risk of AML.<sup id="_ref-18" class="reference"><a href="#_note-18" title="">[18]</a></sup></li></ul>
<a id="Epidemiology" name="Epidemiology"></a><h1>Epidemiology</h1>
<p>Acute myeloid leukemia is a relatively rare cancer. There are approximately 10,500 new cases each year in the <a href="/wiki/United_States" id="w">United States</a>, and the <a href="/wiki/Incidence_(epidemiology)" id="w">incidence</a> rate has remained stable from 1995 through 2005. AML accounts for 1.2% of all cancer deaths in the <a href="/wiki/United_States" id="w">United States</a>.<sup id="_ref-cancerstats_b" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup></p>
<p>The incidence of AML increases with age; the median age at diagnosis is 63 years. AML accounts for about 90% of all acute leukemias in adults, but is rare in children.<sup id="_ref-cancerstats_c" class="reference"><a href="#_note-cancerstats" title="">[1]</a></sup> The rate of <i>therapy-related AML</i> (that is, AML caused by previous chemotherapy) is rising; therapy-related disease currently accounts for about 10–20% of all cases of AML.<sup id="_ref-19" class="reference"><a href="#_note-19" title="">[19]</a></sup> AML is slightly more common in men, with a male-to-female ratio of 1.3:1.<sup id="_ref-20" class="reference"><a href="#_note-20" title="">[20]</a></sup></p>
<p>There is some geographic variation in the incidence of AML. In adults, the highest rates are seen in <a href="/wiki/North_America" id="w">North America</a>, <a href="/wiki/Europe" id="w">Europe</a>, and <a href="/wiki/Oceania" id="w">Oceania</a>, while adult AML is rarer in <a href="/wiki/Asia" id="w">Asia</a> and <a href="/wiki/Latin_America" id="w">Latin America</a>.<sup id="_ref-21" class="reference"><a href="#_note-21" title="">[21]</a></sup><sup id="_ref-22" class="reference"><a href="#_note-22" title="">[22]</a></sup> In contrast, childhood AML is less common in North America and <a href="/wiki/India" id="w">India</a> than in other parts of Asia.<sup id="_ref-23" class="reference"><a href="#_note-23" title="">[23]</a></sup> These differences may be due to population genetics, environmental factors, or a combination of the two.</p>
<p>A hereditary risk for AML appears to exist. There are numerous reports of multiple cases of AML developing in a family at a rate higher than predicted by chance alone.<sup id="_ref-24" class="reference"><a href="#_note-24" title="">[24]</a></sup><sup id="_ref-25" class="reference"><a href="#_note-25" title="">[25]</a></sup><sup id="_ref-26" class="reference"><a href="#_note-26" title="">[26]</a></sup><sup id="_ref-27" class="reference"><a href="#_note-27" title="">[27]</a></sup> The risk of developing AML is increased threefold in <a href="/wiki/First_degree_relative" id="w">first-degree relatives</a> of patients with AML.<sup id="_ref-28" class="reference"><a href="#_note-28" title="">[28]</a></sup></p>
<a id="Pathophysiology" name="Pathophysiology"></a><h1>Pathophysiology</h1>
<p>The malignant cell in AML is the <a href="/wiki/Myeloblast" id="w">myeloblast</a>. In normal <a href="/wiki/Haematopoiesis" id="w">hematopoiesis</a>, the myeloblast is an immature precursor of <a href="/wiki/Myeloid" id="w">myeloid</a> white blood cells; a normal myeloblast will gradually mature into a mature white blood cell. However, in AML, a single myeloblast accumulates genetic changes which &#34;freeze&#34; the cell in its immature state and prevent <a href="/wiki/Cellular_differentiation" id="w">differentiation</a>.<sup id="_ref-29" class="reference"><a href="#_note-29" title="">[29]</a></sup> Such a mutation alone does not cause leukemia; however, when such a &#34;differentiation arrest&#34; is <a href="/wiki/Knudson_hypothesis" id="w">combined with other mutations</a> which disrupt genes controlling <a href="/wiki/Cell_growth" id="w">proliferation</a>, the result is the uncontrolled growth of an immature clone of cells, leading to the clinical entity of AML.<sup id="_ref-30" class="reference"><a href="#_note-30" title="">[30]</a></sup></p>
<p>Much of the diversity and heterogeneity of AML stems from the fact that leukemic transformation can occur at a number of different steps along the differentiation pathway.<sup id="_ref-31" class="reference"><a href="#_note-31" title="">[31]</a></sup> Modern classification schemes for AML recognize that the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.</p>
<p>Specific <a href="/wiki/Cytogenetics" id="w">cytogenetic</a> abnormalities can be found in many patients with AML; the types of chromosomal abnormalities often have <a href="/wiki/Prognosis" id="w">prognostic</a> significance.<sup id="_ref-32" class="reference"><a href="#_note-32" title="">[32]</a></sup> The chromosomal <a href="/wiki/Translocations" id="w">translocations</a> encode abnormal fusion <a href="/wiki/Proteins" id="w">proteins</a>, usually <a href="/wiki/Transcription_factors" id="w">transcription factors</a> whose altered properties may cause the &#34;differentiation arrest.&#34;<sup id="_ref-33" class="reference"><a href="#_note-33" title="">[33]</a></sup> For example, in <a href="/wiki/Acute_promyelocytic_leukemia" id="w">acute promyelocytic leukemia</a>, the t(15;17) translocation produces a PML-RARα <a href="/wiki/Fusion_protein" id="w">fusion protein</a> which binds to the <a href="/wiki/Retinoic_acid" id="w">retinoic acid</a> receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.<sup id="_ref-34" class="reference"><a href="#_note-34" title="">[34]</a></sup></p>
<p>The clinical signs and symptoms of AML result from the fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the development of normal blood cells in the bone marrow.<sup id="_ref-35" class="reference"><a href="#_note-35" title="">[35]</a></sup> This leads to <a href="/wiki/Neutropenia" id="w">neutropenia</a>, <a href="/wiki/Anemia" id="w">anemia</a>, and <a href="/wiki/Thrombocytopenia" id="w">thrombocytopenia</a>. The symptoms of AML are in turn often due to the low numbers of these normal blood elements. In rare cases, patients can develop a <i><a href="/wiki/Chloroma" id="w">chloroma</a></i>, or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.<sup id="_ref-symptoms_d" class="reference"><a href="#_note-symptoms" title="">[9]</a></sup></p>
<a id="Diagnosis" name="Diagnosis"></a><h1>Diagnosis</h1>
<p>The first clue to a diagnosis of AML is typically an abnormal result on a <a href="/wiki/Complete_blood_count" id="w">complete blood count</a>. While an excess of abnormal white blood cells (<a href="/wiki/Leukocytosis" id="w">leukocytosis</a>) is a common finding, and leukemic blasts are sometimes seen, AML can also present with isolated decreases in <a href="/wiki/Platelet" id="w">platelets</a>, <a href="/wiki/Red_blood_cell" id="w">red blood cells</a>, or even with a <i>low</i> white blood cell count (<a href="/wiki/Leukopenia" id="w">leukopenia</a>).<sup id="_ref-36" class="reference"><a href="#_note-36" title="">[36]</a></sup> While a presumptive diagnosis of AML can be made via examination of the peripheral blood smear when there are circulating leukemic blasts, a definitive diagnosis usually requires an adequate bone marrow aspiration and biopsy</p>
<p>A <a href="/wiki/Bone_marrow_examination" id="w">bone marrow examination</a> is often performed to identify the type of abnormal blood cells; however, if there are many leukemic cells circulating in the peripheral blood, a bone marrow <a href="/wiki/Biopsy" id="w">biopsy</a> may not be necessary. Marrow or blood is examined via <a href="/wiki/Light_microscopy" id="w">light microscopy</a> as well as <a href="/wiki/Flow_cytometry" id="w">flow cytometry</a> to diagnose the presence of leukemia, to differentiate AML from other types of leukemia (e.g. <a href="/wiki/Acute_lymphoblastic_leukemia" id="w">acute lymphoblastic leukemia</a>), and to classify the subtype of disease (see below). A sample of marrow or blood is typically also tested for <a href="/wiki/Chromosomal_translocation" id="w">chromosomal translocations</a> by routine <a href="/wiki/Cytogenetics" id="w">cytogenetics</a> or <a href="/wiki/Fluorescent_in_situ_hybridization" id="w">fluorescent in situ hybridization</a>.</p>
<p>The diagnosis and classification of AML can be challenging, and should be performed by a qualified <a href="/wiki/Hematopathologist" id="w">hematopathologist</a> or <a href="/wiki/Hematologist" id="w">hematologist</a>. In straightforward cases, the presence of certain morphologic features (such as <a href="/wiki/Auer_rods" id="w">Auer rods</a>) or specific flow cytometry results can distinguish AML from other leukemias; however, in the absence of such features, diagnosis may be more difficult.<sup id="_ref-37" class="reference"><a href="#_note-37" title="">[37]</a></sup></p>
<p>According to the widely used <a href="/wiki/WHO" id="w">WHO</a> criteria, the diagnosis of AML is established by demonstrating involvement of more than 20% of the blood and/or bone marrow by leukemic <a href="/wiki/Myeloblast" id="w">myeloblasts</a>.<sup id="_ref-38" class="reference"><a href="#_note-38" title="">[38]</a></sup> AML must be carefully differentiated from &#34;pre-leukemic&#34; conditions such as <a href="/wiki/Myelodysplastic_syndrome" id="w">myelodysplastic</a> or <a href="/wiki/Myeloproliferative_syndrome" id="w">myeloproliferative</a> syndromes, which are treated differently.</p>
<p>Because <a href="/wiki/Acute_promyelocytic_leukemia" id="w">acute promyelocytic leukemia</a> (APL) has the highest curability and requires a unique form of treatment, it is important to quickly establish or exclude the diagnosis of this subtype of leukemia. <a href="/wiki/Fluorescent_in_situ_hybridization" id="w">Fluorescent in situ hybridization</a> performed on blood or bone marrow is often used for this purpose, as it readily identifies the <a href="/wiki/Chromosomal_translocation" id="w">chromosomal translocation</a> (t[15;17]) that characterizes APL.<sup id="_ref-39" class="reference"><a href="#_note-39" title="">[39]</a></sup></p>
<a id="Classification" name="Classification"></a><h1>Classification</h1>
<p>The two most commonly used classification schemata for AML, <a href="/wiki/As_of_2006" id="w">as of 2006</a>, are the older French-American-British (FAB) system and the newer <a href="/wiki/World_Health_Organization" id="w">World Health Organization</a> (WHO) system.</p>
<a id="French-American-British_classification" name="French-American-British_classification"></a><h2>French-American-British classification</h2>
<p>The <a href="/wiki/French-American-British_classification" id="w"> French-American-British (FAB) classification</a> system divided AML into 8 subtypes, M0 through to M7, based on the type of cell from which the leukemia developed and its degree of maturity. This is done by examining the appearance of the malignant cells under <a href="/wiki/Light_microscopy" id="w">light microscopy</a> and/or by using <a href="/wiki/Cytogenetics" id="w">cytogenetics</a> to characterize any underlying chromosomal abnormalities. The subtypes have varying prognoses and responses to therapy. Although the WHO classification (see below) may be more useful, the FAB system is still widely used as of mid-2006.</p>
<p>The eight FAB subtypes are:<sup id="_ref-40" class="reference"><a href="#_note-40" title="">[40]</a></sup>
</p>
<ul>
<li>M0 (<a href="/wiki/Undifferentiated" id="w">undifferentiated</a> AML)</li>
<li>M1 (myeloblastic, without maturation)</li>
<li><a href="/wiki/M2_AML" id="w">M2</a> (myeloblastic, with maturation)</li>
<li>M3 (promyelocytic), or <a href="/wiki/Acute_promyelocytic_leukemia" id="w">acute promyelocytic leukemia</a> (APL)</li>
<li>M4 (myelomonocytic)</li>
<li>M4eo (myelomonocytic together with bone marrow <a href="/wiki/Eosinophil" id="w">eosinophilia</a>)</li>
<li>M5 <a href="/wiki/Monoblastic_leukemia" id="w">monoblastic leukemia</a> (M5a) or <a href="/wiki/Monocytic_leukemia" id="w">monocytic leukemia</a> (M5b)</li>
<li>M6 (erythrocytic), or <a href="/wiki/Erythroleukemia" id="w">erythroleukemia</a></li>
<li>M7 (megakaryoblastic)</li></ul>
<a id="World_Health_Organization_classification" name="World_Health_Organization_classification"></a><h2>World Health Organization classification </h2>
<p>The <a href="/wiki/World_Health_Organization" id="w">World Health Organization</a> (WHO) classification of acute myeloid leukemia attempts to be more clinically useful and to produce more meaningful prognostic information than the FAB criteria. Each of the WHO categories contains numerous descriptive sub-categories of interest to the <a href="/wiki/Hematopathologist" id="w">hematopathologist</a> and <a href="/wiki/Oncologist" id="w">oncologist</a>; however, most of the clinically significant information in the WHO schema is communicated via categorization into one of the five subtypes listed below.</p>
<p>The WHO subtypes of AML are:<sup id="_ref-41" class="reference"><a href="#_note-41" title="">[41]</a></sup>
</p>
<ul>
<li><b>AML with characteristic genetic abnormalities</b>, which includes AML with translocations between chromosome 8 and 21 [t(8;21)], inversions in chromosome 16 [inv(16)], or translocations between chromosome 15 and 17 [t(15;17)]. Patients with AML in this category generally have a high rate of remission and a better prognosis compared to other types of AML.</li>
<li><b>AML with multilineage dysplasia</b>. This category includes patients who have had a prior <a href="/wiki/Myelodysplastic_syndrome" id="w">myelodysplastic syndrome</a> (MDS) or <a href="/wiki/Myeloproliferative_disease" id="w">myeloproliferative disease</a> (MPD) that transforms into AML. This category of AML occurs most often in elderly patients and often has a worse prognosis.</li>
<li><b>AML and MDS, therapy-related</b>. This category includes patients who have had prior chemotherapy and/or radiation and subsequently develop AML or MDS. These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis.</li>
<li><b>AML not otherwise categorized</b>. Includes subtypes of AML that do not fall into the above categories.</li>
<li><b>Acute leukemias of ambiguous lineage</b>. Acute leukemias of ambiguous lineage (also known as mixed phenotype or biphenotypic acute leukemia) occur when the leukemic cells can not be classified as either myeloid or lymphoid cells, or where both types of cells are present.</li></ul>
<a id="Prognosis" name="Prognosis"></a><h1>Prognosis</h1>
<p><div style="wigth:125px"><a class="internal" href="/wiki/Image:125px-9%3B11.rhyax.jpg" title="Chromosomal translocation (9;11), associated with AML"><img src="http://en.wikipedia.org/wiki/125px-9%3B11.rhyax.jpg" alt="Chromosomal translocation (9;11), associated with AML" title="Chromosomal translocation (9;11), associated with AML" class="location-right type-thumb" width="125px" />
</a>
<div class="thumbcaption">Chromosomal translocation (9;11), associated with AML</div></div>

Acute myeloid leukemia is a curable disease; the chance of cure for a specific patient depends on a number of prognostic factors.<sup id="_ref-prog_a" class="reference"><a href="#_note-prog" title="">[42]</a></sup></p>
<a id="Cytogenetics_and_prognosis_in_AML" name="Cytogenetics_and_prognosis_in_AML"></a><h2>Cytogenetics and prognosis in AML</h2>
<p>The single most important prognostic factor in AML is <a href="/wiki/Cytogenetics" id="w">cytogenetics</a>, or the chromosomal structure of the leukemic cell. Certain cytogenetic abnormalities are associated with very good outcomes (for example, the (15;17) translocation in <a href="/wiki/Acute_promyelocytic_leukemia" id="w">acute promyelocytic leukemia</a>). About half of AML patients have &#34;normal&#34; cytogenetics; they fall into an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor prognosis and a high risk of relapse after treatment.<sup id="_ref-43" class="reference"><a href="#_note-43" title="">[43]</a></sup><sup id="_ref-44" class="reference"><a href="#_note-44" title="">[44]</a></sup><sup id="_ref-45" class="reference"><a href="#_note-45" title="">[45]</a></sup></p>
<p>The first publication to address cytogenetics and prognosis was the MRC trial of 1998:<sup id="_ref-46" class="reference"><a href="#_note-46" title="">[46]</a></sup>
</p>
<div style="page-break-inside:	avoid;">
<table class="wikitable">
<tr>
<th>Risk Category</th>
<th>Abnormality</th>
<th>5-year survival</th>
<th>Relapse rate</th></tr>
<tr>
<td>Favorable</td>
<td>t(8;21), t(15;17), inv(16)</td>
<td>70%</td>
<td>33%</td></tr>
<tr>
<td>Intermediate</td>
<td>Normal, +8, +21, +22, del(7q), del(9q), Abnormal 11q23, all other structural or numerical changes</td>
<td>48%</td>
<td>50%</td></tr>
<tr>
<td>Adverse</td>
<td>-5, -7, del(5q), Abnormal 3q, Complex cytogenetics</td>
<td>15%</td>
<td>78%</td></tr></table></div>

<p>Later, the <a href="/wiki/Southwest_Oncology_Group" id="w">Southwest Oncology Group</a> and <a href="/wiki/Eastern_Cooperative_Oncology_Group" id="w">Eastern Cooperative Oncology Group</a>,<sup id="_ref-47" class="reference"><a href="#_note-47" title="">[47]</a></sup> and later still, <a href="/wiki/Cancer_and_Leukemia_Group_B" id="w">Cancer and Leukemia Group B</a> published other, mostly overlapping lists of cytogenetics prognostication in leukemia<sup id="_ref-48" class="reference"><a href="#_note-48" title="">[48]</a></sup></p>
<a id="Antecedent_MDS_and_prognosis" name="Antecedent_MDS_and_prognosis"></a><h2>Antecedent MDS and prognosis</h2>
<p>AML which arises from a pre-existing <a href="/wiki/Myelodysplastic_syndrome" id="w">myelodysplastic syndrome</a> or <a href="/wiki/Myeloproliferative_disease" id="w">myeloproliferative disease</a> (so-called <i>secondary AML</i>) has a worse <a href="/wiki/Prognosis" id="w">prognosis</a>, as does <i>treatment-related AML</i> arising after chemotherapy for another previous malignancy. Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities.<sup id="_ref-49" class="reference"><a href="#_note-49" title="">[49]</a></sup><sup id="_ref-50" class="reference"><a href="#_note-50" title="">[50]</a></sup><sup id="_ref-51" class="reference"><a href="#_note-51" title="">[51]</a></sup></p>
<a id="Other_prognostic_markers" name="Other_prognostic_markers"></a><h2>Other prognostic markers</h2>
<p>In some studies, age &#62;60 years and elevated <a href="/wiki/Lactate_dehydrogenase" id="w">lactate dehydrogenase</a> level were also associated with poorer outcomes.<sup id="_ref-52" class="reference"><a href="#_note-52" title="">[52]</a></sup> As with most forms of cancer, performance status (i.e. the general physical condition and activity level of the patient) plays a major role in prognosis as well.</p>
<p><a href="/wiki/FLT3" id="w">FLT3</a> internal tandem duplications (ITDs) have been shown to confer a poorer prognosis in AML.<sup id="_ref-53" class="reference"><a href="#_note-53" title="">[53]</a></sup> Treating these patients with more aggressive therapy, such as stem-cell transplantation in first remission, has not been shown to enhance long-term survival, so this prognostic feature is of uncertain clinical significance at this point.<sup id="_ref-54" class="reference"><a href="#_note-54" title="">[54]</a></sup>  ITDs of <a href="/wiki/FLT3" id="w">FLT3</a> may be associated with <a href="/wiki/Leukostasis" id="w">leukostasis</a>.<sup id="_ref-pmid17942876_a" class="reference"><a href="#_note-pmid17942876" title="">[55]</a></sup></p>
<p>Researchers are investigating the clinical significance of <a href="/wiki/C-KIT" id="w">c-KIT</a> mutations<sup id="_ref-56" class="reference"><a href="#_note-56" title="">[56]</a></sup> in AML. These are prevalent, and clinically relevant because of the availability of <a href="/wiki/Tyrosine_kinase_inhibitors" id="w">tyrosine kinase inhibitors</a>, such as <a href="/wiki/Sunitinib" id="w">sunitinib</a> and <a href="/wiki/Imatinib" id="w">imatinib</a> that can block the activity of <a href="/wiki/C-KIT" id="w">c-KIT</a> pharmacologically.</p>
<p>Other genes being investigated as prognostic factors or therapeutic targets include CEBPA, BAALC, ERG, and NPM1.</p>
<a id="Overall_expectation_of_cure" name="Overall_expectation_of_cure"></a><h2>Overall expectation of cure</h2>
<p>Cure rates in clinical trials have ranged from 20–45%;<sup id="_ref-57" class="reference"><a href="#_note-57" title="">[57]</a></sup><sup id="_ref-58" class="reference"><a href="#_note-58" title="">[58]</a></sup> however, it should be noted that clinical trials often include only younger patients and those able to tolerate aggressive therapies. The overall cure rate for all patients with AML (including the elderly and those unable to tolerate aggressive therapy) is likely lower. Cure rates for promyelocytic leukemia can be as high as 98%.<sup id="_ref-59" class="reference"><a href="#_note-59" title="">[59]</a></sup></p>
<a id="Treatment" name="Treatment"></a><h1>Treatment</h1>
<p>Treatment of AML consists primarily of <a href="/wiki/Chemotherapy" id="w">chemotherapy</a>, and is divided into two phases: <i>induction</i> and <i>postremission</i> (or <i>consolidation</i>) therapy. The goal of <i>induction</i> therapy is to achieve a complete remission by reducing the amount of leukemic cells to an undetectable level; the goal of <i>consolidation</i> therapy is to eliminate any residual undetectable disease and achieve a cure.</p>
<a id="Induction" name="Induction"></a><h2>Induction</h2>
<p><a href="/wiki/As_of_2006" id="w">As of 2006</a>, all FAB subtypes except M3 are usually given induction chemotherapy with <a href="/wiki/Cytarabine" id="w">cytarabine</a> (ara-C) and an <a href="/wiki/Anthracycline" id="w">anthracycline</a> (such as <a href="/wiki/Daunorubicin" id="w">daunorubicin</a> or <a href="/wiki/Idarubicin" id="w">idarubicin</a>).<sup id="_ref-treatment_a" class="reference"><a href="#_note-treatment" title="">[60]</a></sup> Other alternatives, including high-dose ara-C alone, may also be used.<sup id="_ref-61" class="reference"><a href="#_note-61" title="">[61]</a></sup><sup id="_ref-62" class="reference"><a href="#_note-62" title="">[62]</a></sup> Because of the toxic effects of therapy, including <a href="/wiki/Myelosuppression" id="w">myelosuppression</a> and an increased risk of infection, induction chemotherapy may not offered to the very elderly. Induction chemotherapy usually requires a hospitalization of about 1 month to receive the chemotherapy and recover from its side effects.</p>
<p>Induction chemotherapy is known as &#34;7 and 3&#34; because the <a href="/wiki/Cytarabine" id="w">cytarabine</a> is given as a continuous IV infusion for seven consecutive days, while the <a href="/wiki/Anthracycline" id="w">anthracycline</a> is given for three consecutive days as an IV push. Up to 70% of patients will achieve a remission with this protocol.<sup id="_ref-63" class="reference"><a href="#_note-63" title="">[63]</a></sup></p>
<p>The M3 subtype of AML, also known as <a href="/wiki/Acute_promyelocytic_leukemia" id="w">acute promyelocytic leukemia</a>, is almost universally treated with the drug <a href="/wiki/ATRA" id="w">ATRA</a> (all-<i>trans</i>-retinoic acid) in addition to induction chemotherapy.<sup id="_ref-64" class="reference"><a href="#_note-64" title="">[64]</a></sup><sup id="_ref-65" class="reference"><a href="#_note-65" title="">[65]</a></sup><sup id="_ref-66" class="reference"><a href="#_note-66" title="">[66]</a></sup> Care must be taken to prevent disseminated intravascular coagulation (<a href="/wiki/Disseminated_intravascular_coagulation" id="w">DIC</a>), complicating the treatment of <a href="/wiki/Acute_promyelocytic_leukemia" id="w">APL</a> when the promyelocytes release the contents of their granules into the peripheral circulation. <a href="/wiki/APL" id="w">APL</a> is eminently curable with well-documented treatment protocols.</p>
<p>The goal of the induction phase is to reach a <i>complete remission</i>. Complete remission does not mean that the disease has been cured; rather, it signifies that no disease can be detected with available diagnostic methods (i.e., &#60;5% leukemic cells remain in the <a href="/wiki/Bone_marrow" id="w">bone marrow</a>).<sup id="_ref-treatment_b" class="reference"><a href="#_note-treatment" title="">[60]</a></sup> Complete remission is obtained in about 50%–75% of newly diagnosed adults, although this may vary based on the prognostic factors described above.<sup id="_ref-67" class="reference"><a href="#_note-67" title="">[67]</a></sup></p>
<p>The durability of remission depends on the prognostic features of the original leukemia. In general, all remissions will fail without consolidation (post-remission) chemotherapy, and consolidation has become an important component of treatment.<sup id="_ref-68" class="reference"><a href="#_note-68" title="">[68]</a></sup></p>
<a id="Consolidation" name="Consolidation"></a><h2>Consolidation</h2>
<p>Even after complete remission is achieved, leukemic cells likely remain in numbers too small to be detected with current diagnostic techniques. If no further <i>postremission</i> or consolidation therapy is given, almost all patients will eventually relapse.<sup id="_ref-69" class="reference"><a href="#_note-69" title="">[69]</a></sup> Therefore, more therapy is necessary to eliminate non-detectable disease and prevent relapse &#8212; that is, to achieve a cure.</p>
<p>The specific type of postremission therapy is individualized based on a patient&#39;s prognostic factors (see above) and general health. For good-prognosis leukemias (i.e. inv(16), t(8;21), and t(15;17)), patients will typically undergo an additional 3–5 courses of intensive chemotherapy, known as <i>consolidation</i> chemotherapy.<sup id="_ref-70" class="reference"><a href="#_note-70" title="">[70]</a></sup><sup id="_ref-nccn_a" class="reference"><a href="#_note-nccn" title="">[71]</a></sup> For patients at high risk of relapse (e.g. those with high-risk cytogenetics, underlying MDS, or therapy-related AML), <a href="/wiki/Bone_marrow_transplant" id="w">allogeneic stem cell transplantation</a> is usually recommended if the patient is able to tolerate a transplant and has a suitable donor. The best postremission therapy for intermediate-risk AML (normal cytogenetics or cytogenetic changes not falling into good-risk or high-risk groups) is less clear and depends on the specific situation, including the age and overall health of the patient, the patient&#39;s personal values, and whether a suitable stem cell donor is available.<sup id="_ref-nccn_b" class="reference"><a href="#_note-nccn" title="">[71]</a></sup></p>
<a id="Relapsed_AML" name="Relapsed_AML"></a><h2>Relapsed AML</h2>
<p>Despite aggressive therapy, however, only 20%–30% of patients enjoy long-term disease-free survival. For patients with relapsed AML, the only proven potentially curative therapy is a <a href="/wiki/Stem_cell_transplant" id="w">stem cell transplant</a>, if one has not already been performed.<sup id="_ref-relapse_a" class="reference"><a href="#_note-relapse" title="">[72]</a></sup><sup id="_ref-73" class="reference"><a href="#_note-73" title="">[73]</a></sup><sup id="_ref-74" class="reference"><a href="#_note-74" title="">[74]</a></sup> In 2000, <a href="/wiki/Mylotarg" id="w">Mylotarg</a> (gemtuzumab zogamicin) was approved in the United States for patients aged more than 60 years with relapsed AML who are not candidates for high-dose chemotherapy.<sup id="_ref-75" class="reference"><a href="#_note-75" title="">[75]</a></sup></p>
<p>Patients with relapsed AML who are not candidates for stem cell transplantion, or who have relapsed after a stem cell transplant, should be strongly considered for enrollment in a <a href="/wiki/Clinical_trial" id="w">clinical trial</a>, as conventional treatment options are limited. Agents under investigation include cytotoxic drugs such as <a href="/wiki/Clofarabine" id="w">clofarabine</a> as well as <a href="/wiki/Targeted_therapy" id="w">targeted therapies</a> such as <a href="/wiki/Farnesyltransferase_inhibitor" id="w">farnesyl transferase inhibitors</a>, decitabine, and inhibitors of MDR1 (multidrug-resistance protein). Since treatment options for relapsed AML are so limited, another option which may be offered is <a href="/wiki/Palliative_care" id="w">palliative care</a>.</p>
<p>For relapsed acute promyelocytic leukemia (APL), <a href="/wiki/Arsenic_trioxide" id="w">arsenic trioxide</a> has been tested in trials and approved by the <a href="/wiki/Food_and_Drug_Administration" id="w">Food and Drug Administration</a>. Like ATRA, arsenic trioxide does not work with other subtypes of AML.<sup id="_ref-76" class="reference"><a href="#_note-76" title="">[76]</a></sup></p>
<a id="See_also" name="See_also"></a><h1>See also</h1>

<ul>
<li><a href="/wiki/Chloroma" id="w">Chloroma</a></li>
<li><a href="/wiki/Chronic_myelogenous_leukemia" id="w">Chronic myelogenous leukemia</a></li>
<li><a href="/wiki/Acute_lymphoblastic_leukemia" id="w">Acute lymphoblastic leukemia</a></li></ul>
<a id="Further_reading" name="Further_reading"></a><h1>Further reading</h1>

<ul>
<li>{{cite book}}</li>
<li>{{cite book}}</li></ul>
<a id="References" name="References"></a><h1>References</h1>
<p>{{reflist}}</p>
<a id="External_links" name="External_links"></a><h1>External links</h1>

<ul>
<li><a class="externallink" href="http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?rnav=criov&#38;dt=82" rel="nofollow" title="http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?rnav=criov&#38;dt=82">American Cancer Society page on Acute Myeloid Leukemia</a></li>
<li><a class="externallink" href="http://leukemia.acor.org/" rel="nofollow" title="http://leukemia.acor.org/">Association of Cancer Online Resource (ACOR) Leukemia Links</a></li>
<li><a class="externallink" href="http://www.leukemia-lymphoma.org/all_page?item_id=8459" rel="nofollow" title="http://www.leukemia-lymphoma.org/all_page?item_id=8459">Leukemia &#38; Lymphoma Society page on Acute Myeloid Leukemia</a></li>
<li><a class="externallink" href="http://www.cchs.net/health/health-info/docs/1400/1403.asp?index=6211" rel="nofollow" title="http://www.cchs.net/health/health-info/docs/1400/1403.asp?index=6211">Childhood Acute Myeloid Leukemia</a></li>
<li><a class="externallink" href="http://www.marrow.org" rel="nofollow" title="http://www.marrow.org">National Marrow Donor Program</a></li>
<li><a class="externallink" href="http://www.bmtinfonet.org/" rel="nofollow" title="http://www.bmtinfonet.org/">Blood &#38; Marrow Transplant Information Network</a></li>
<li><a class="externallink" href="http://www.cancer.gov/cancer_information/doc.aspx?viewid=4d3f920e-87d6-4b6a-a2fe-74c6efa53398&#38;version=1" rel="nofollow" title="http://www.cancer.gov/cancer_information/doc.aspx?viewid=4d3f920e-87d6-4b6a-a2fe-74c6efa53398&#38;version=1">National Cancer Institute (NCI) PDQ statement on AML for health professionals</a></li></ul>
<p>{{Hematology}}
{{Hematological malignancy histology}}
{{featured article}}</p>
<p>

</p>
<p>{{Link FA}}</p>
<p><a href="http://ar.wikipedia.org/wiki/ا%D8%A8%D9%8A%D8%B6%D8%A7%D8%B6_%D8%A7%D9%84%D8%AF%D9%85_%D8%A7%D9%84%D9%86%D9%82%D9%88%D9%8A_%D8%A7%D9%84%D8%AD%D8%A7%D8%AF">ar:ابيضاض الدم النقوي الحاد</a>
<a href="http://ca.wikipedia.org/wiki/Leuc%C3%A8mia_aguda_mieloide">ca:Leucèmia aguda mieloide</a>
<a href="http://de.wikipedia.org/wiki/Akute_myeloische_Leuk%C3%A4mie">de:Akute myeloische Leukämie</a>
<a href="http://es.wikipedia.org/wiki/Leucemia_mieloide_aguda">es:Leucemia mieloide aguda</a>
<a href="http://he.wikipedia.org/wiki/ל%D7%95%D7%A7%D7%9E%D7%99%D7%94_%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%90%D7%99%D7%93%D7%99%D7%AA_%D7%97%D7%A8%D7%99%D7%A4%D7%94">he:לוקמיה מיאלואידית חריפה</a>
<a href="http://ja.wikipedia.org/wiki/急%E6%80%A7%E9%AA%A8%E9%AB%84%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85">ja:急性骨髄性白血病</a>
<a href="http://pl.wikipedia.org/wiki/Ostra_bia%C5%82aczka_szpikowa">pl:Ostra białaczka szpikowa</a>
<a href="http://pt.wikipedia.org/wiki/Leucemia_miel%C3%B3ide_aguda">pt:Leucemia mielóide aguda</a>
<a href="http://sr.wikipedia.org/wiki/А%D0%BA%D1%83%D1%82%D0%BD%D0%B0_%D0%BC%D0%B8%D1%98%D0%B5%D0%BB%D0%BE%D1%86%D0%B8%D1%82%D0%BD%D0%B0_%D0%BB%D0%B5%D1%83%D0%BA%D0%B5%D0%BC%D0%B8%D1%98%D0%B0">sr:Акутна мијелоцитна леукемија</a>
<a href="http://sv.wikipedia.org/wiki/Akut_myeloisk_leukemi">sv:Akut myeloisk leukemi</a>
<a href="http://zh.wikipedia.org/wiki/急%E6%80%A7%E9%AA%A8%E9%AB%93%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85">zh:急性骨髓性白血病</a>
</p>